Innovation Transformed into Vaccines
JN conducted NmVac A/C/Y/W-135™ Meningitis vaccine trials in Burkina Faso and Niger during 2003-2004.
Protective sero-conversion successfully occurred and was tested and recorded
in vaccinated individuals during a spontaneous disease outbreak.
JN the founder of the biotechnology industry, is a company with a decade track record of delivering on the promise of biotechnology. Today, JN is among the world's leading biotech companies, with innovated diagnostics and vaccine products for detection and prevention of the most common diseases. With its strength in all areas of the product development process - from research to manufacturing and commercialization - JN continues to transform the possibilities of biotechnology into improved realities for human health.
PLEASE BACK TO GLOBAL HEALTH PAGE